Calling it a "temporary setback," "easily remedied" and "relatively immaterial," analysts played down the negative impact of the FDA's refuse-to-file (RTF) letter to Gilead Sciences Inc. for its new drug application (NDA) seeking approval of HIV single-tablet regimen Truvada (emtricitabine/tenofovir disoproxil fumarate) plus Tibotec Pharmaceuticals Ltd.'s TMC278 (rilpivirine).